Antithrombin alternatives in STEMI

The Lancet

Volumn 378, Issue 9792, 2011, Pages 643-645

  Stone, Gregg W ^a   Ohman, E Magnus ^b  

^a NewYork Presbyterian Hospital   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ENOXAPARIN; FIBRINOGEN RECEPTOR; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; CATHETER THROMBOSIS; CLINICAL TRIAL; CORONARY STENT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; FIBRINOLYSIS; HEART INFARCTION; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS;

EID: 80051964417     PISSN: 0140-6736     EISSN: 1474-547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61059-3     Document Type: Note

References (14)

1. C Gao, B Boylan, J Fang et al. Heparin promotes platelet responsiveness by potentiating αIIβ3-mediated outside-in signaling Blood 117 2011 4946 4952
2. G De Luca, H Suryapranata, GW Stone et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials JAMA 293 2005 1759 1765
3. S Yusuf, SR Mehta, S Chrolavicius et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA 295 2006 1519 1530
4. C Kimmelstiel, P Zhang, NK Kapur et al. Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention Circ Cardiovasc Interv 4 2011 171 179
5. GW Stone, B Witzenbichler, G Guagliumi on behalf of the HORIZONS-AMI Trial Investigators Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial Lancet 377 2011 2193 2204
6. JA Rassen, MA Mittleman, RJ Glynn, MA Brookhart, S Schneeweiss Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention Eur Heart J 31 2010 561 572
7. EM Antman, DA Morrow, CH McCabe et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction N Engl J Med 354 2006 1477 1488
8. JJ Ferguson, RM Califf, EM Antman et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial JAMA 292 2004 45 54
9. G Montalescot, HD White, R Gallo et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention N Engl J Med 355 2006 1006 1017 (Pubitemid 44343544)
10. G Montalescot, U Zeymer, J Silvain et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial Lancet 378 2011 693 703
11. GD Dangas, R Mehran, E Nikolsky et al. Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis J Am Coll Cardiol 57 2011 2309 2316
12. G Montalescot, SD Wiviott, E Braunwald for the TRITON-TIMI 38 investigators Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
13. PG Steg, S James, RA Harrington et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis Circulation 122 2010 2131 2141
14. SJ Pocock, R Mehran, TC Clayton et al. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial Circulation 121 2010 43 51